Jesús Rebollo

Building -

[Jesús Rebollo @JesusRebolloG]

Arrancamos 2025 con una gran noticia.
Después de muchos meses en las trincheras, ya puedo anunciar que @antaivb y @JME_Ventures serán nuestros socios para lanzar Balance. Queremos ayudar a millones de personas en su lucha contra la obesidad.
https://t.co/prx01GnzUS

[Jesús Rebollo @JesusRebolloG]

No paran de salir nuevos beneficios derivados de los GLP-1 que van mucho más allá de la pérdida de peso

[Eric Topol @EricTopol]

A new study links GLP-1 drugs and 30-35% reduced incidence of breast cancer, using matched-pair propensity analysis
https://t.co/AjNYlDM3A3
Confirms other association studies but still no proof

[Jesús Rebollo @JesusRebolloG]

@samuelgil 💯
Muy interesante también las pruebas con dosis altas de vitamina C para ciertos tipos de cancer

[Jesús Rebollo @JesusRebolloG]

@samuelgil Poca duda aquí 👈 🤛

[Martinez @MrtnzAlvrz]

Miré los muros de la patria mía…

Qué dolor.

[Jesús Rebollo @JesusRebolloG]

@Jason Im in

[J. L. Martín Nogales @jlmartinnogales]

Así se extendió por la Tierra el ser humano. Esas fueron sus rutas.

[Jesús Rebollo @JesusRebolloG]

@XMihura Estamos dentro !

[Jesús Rebollo @JesusRebolloG]

The Self-Help Trap: What 20 Years of “Optimizing” Has Taught Me https://t.co/ULbkWkSB4G

[Jesús Rebollo @JesusRebolloG]

Esta es una de las mejores historias que he visto (si es 100% real)
Estoy convencido que esta industria no está viendo el tsunami que se le viene encima.

[Aakash Gupta @aakashgupta]

A tech consultant in Sydney spent $3,000 and two months to do what Moderna has spent billions trying to scale.

Paul Conyngham adopted Rosie, a staffy-Shar Pei cross, from a shelter in 2019. In 2024, tumors started growing on her back leg. Mast cell cancer, the most common skin cancer in dogs. He tried surgery, chemo, immunotherapy. Nothing shrank the tumors. Just slowed them down while the bills stacked into the tens of thousands.

So he opened ChatGPT and asked it how to cure his dog’s cancer.

The AI didn’t cure anything. What it did was compress months of literature review into hours. It suggested genomic sequencing, walked him through neoantigen identification, helped him build a research pipeline that would normally require a postdoc and a lab budget. He paid $3,000 to sequence Rosie’s tumor DNA at UNSW’s Ramaciotti Centre, then ran the mutations through AlphaFold to model the protein structures. A computational biology professor at UNSW saw his analysis and was, in his own words, gobsmacked that someone with zero biology training had assembled the whole thing.

Then came the part nobody expects. The science was the easy half. Australian ethics approval to run a drug trial on your own pet took three months. Two hours every night after work, filling out a 100-page application. The red tape was harder than designing the vaccine.

Once he cleared that, Páll Thordarson at the UNSW RNA Institute built a custom mRNA vaccine from Conyngham’s data. Sequencing to finished vaccine: less than two months. Conyngham drove 10 hours to deliver Rosie for her first injection in December. One month later, the tennis-ball-sized tumor on her leg had shrunk 75%.

Here’s where the numbers get interesting. Moderna and Merck just reported five-year data on their personalized mRNA cancer vaccine for melanoma. It encodes up to 34 neoantigens per patient. The Phase III trial is fully enrolled. Projected cost per patient: $100,000 to $300,000. Their pipeline is worth an estimated $2.3 billion in annual sales by 2031.

Conyngham did a version of the same workflow for his dog. Sequenced the tumor. Identified the neoantigens. Built a custom mRNA construct. Total cost: $3,000 for sequencing plus university lab time. The gap between those two numbers is where AI is about to rearrange the entire cost structure of precision medicine.

The regulatory moat is real. Conyngham could do this because veterinary experimental treatments face lighter scrutiny than human medicine. There’s no FDA Phase I-III gauntlet for a one-off compassionate use case on a dog. But the technical workflow, tumor sequencing to neoantigen prediction to mRNA synthesis, is converging toward something a motivated person with the right AI tools can orchestrate in weeks instead of years.

One guy, a rescue dog, and a $20/month ChatGPT subscription just produced a proof of concept that the pharmaceutical industry has spent a decade and billions of dollars building toward. The vaccine worked. The tumor shrank. And the only reason it happened is because a dog owner loved his dog enough to spend three months fighting paperwork.

[Jesús Rebollo @JesusRebolloG]

@samuelgil Yo veo clarísimo la suma positiva kettlebell

[Caitlin Kalinowski @kalinowski007]

I resigned from OpenAI. I care deeply about the Robotics team and the work we built together. This wasn’t an easy call. AI has an important role in national security. But surveillance of Americans without judicial oversight and lethal autonomy without human authorization are lines that deserved more deliberation than they got. This was about principle, not people. I have deep respect for Sam and the team, and I’m proud of what we built together.

[Jesús Rebollo @JesusRebolloG]

@samuelgil Coincidencias.
Una mujer de la que me hablan maravillas y con la que me veré en breve. https://t.co/8uEN0watcl

[Power to the People ☭🕊 @ProudSocialist]

Rubio: “Iran is run by religious fanatics.”

The White House right now:

[Jesús Rebollo @JesusRebolloG]

@EstebanCervi Si estás en Madrid avisa

[Eric Topol @EricTopol]

The combination of GLP-1 drugs (such as Ozempic) and healthy lifestyle factors was associated with less major adverse cardiovascular events in ~100,000 people with T2D
@TheLancetEndo https://t.co/phNzEBy7zY

[Jesús Rebollo @JesusRebolloG]

A mi hijo le han otorgado la condición de Deportista de Alto Nivel. Orgulloso es poco.

[Jesús Rebollo @JesusRebolloG]

@drconnealymd Can you link to the study ?

[Jesús Rebollo @JesusRebolloG]

@Otrosvendran 100% ese es mi caso

[Jesús Rebollo @JesusRebolloG]

@ElNickelNFL @deionmarco @Rubenibg Solo en YT?

[Jesús Rebollo @JesusRebolloG]

No pierde el tiempo @sama

[Peter Steinberger 🦞 @steipete]

I'm joining @OpenAI to bring agents to everyone. @OpenClaw is becoming a foundation: open, independent, and just getting started.🦞
https://t.co/XOc7X4jOxq